ArticleEuropean journal of haematology2026
Restricted Expression of the Constant Region 1 of T-Cell Receptor β by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Atypical and Suspicious for Malignancy Categories of the WHO Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Review of their Diagnostic Utility, Limitations, and Clinical Impact.Diagnostic cytopathology · 2026Review
- Restricted Expression of the Constant Region 1 of T-Cell Receptor β by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value.European journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo determine the diagnostic value of disclosing monotypic T-cell populations by expression analysis of the constant region 1 of T-cell receptor β (TRBC1) by flow cytometry, for the detection of T-cell neoplasms, in a routine hematopathology practice setting.
methodsA panel of antibodies ECD-CD16/PECy5.5-CD4/PECy7-CD2/APCAF700-CD7/KO-CD8/FITC-TCRγδ/PE-TRBC1/APC-CD26/APC-CD57/APC-CD30/APCH7-CD45/BV421-CD3 was applied. One thousand and twenty-nine cases investigated during 26 months were reviewed and categorized as monotypic or polytypic depending on the expression of TRBC1 in all identifiable CD3+ T-cell subsets.
resultsAlthough TRBC1 restriction proved to be sensitive (90.7%) with a high negative predictive value (99.1%), in some T-cell neoplasms, particularly those with significant inflammation, including angioimmunoblastic T-cell lymphoma, monotypic T-cells were not detected. The specificity was high (95.6%) albeit with a modest positive predictive value (67.1%), reflecting T-cell clones of uncertain significance (T-CUS) without T-cell neoplasm. Of these clones, 53.6% exhibited a T-cell large granular lymphocytic leukemia-like phenotype, most commonly found in the peripheral blood or bone marrow, while others were identified in association with unrelated primary tumors or other comorbidities. Seventy-nine percent of the T-CUS cases remained stable over time during 1-77 months of follow-up.
conclusionIncluding TRBC1 antibodies in a routine flow cytometry panel facilitates the identification of T-cell neoplasms. The analysis must be interpreted within its clinical context since T-cell lymphomas with a small and sometimes surface CD3-negative neoplastic T cell population, may display normal patterns of TRBC1-expression with a background of reactive T cells. Conversely, monotypic T-cells can be found in the absence of T-cell neoplasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.